Akebia Therapeutics, Inc. AKBA 深 滬
已收盤 07-02 16:00:00 美东时间
1.24
+0.030
+2.48%
華盛通- 最 高1.24
- 今 開1.22
- 成交量 419.87万股
- 最 低 1.16
- 昨 收 1.21
- 總市值 3.33亿
- 52周最高 4.04
- 市盈率 靜 --
- 換手率 1.57%
- 52周最低 0.8227
- 委 比 10.16%
- 總股本 2.68亿
- 歷史最高 31.00
- 量 比 0.67
- 振 幅 6.61%
- 歷史最低 0.241
- 每 手 1
- 風險率 0.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Insider Shake-Up: GC, Akebia, Perion, Paychex, Arqit
Insiders have been trading these 5 stocks: (($STRL)), (($AKBA)), (($PERI)), (($...
07-04 21:01
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Akebia Therapeutics granted stock options to three new employees on June 30, 2026, allowing them to purchase a total of 125,600 shares at $1.14 per share. The options vest over four years, with 25% vesting after the first year and the remaining 75% vesting quarterly, contingent on continued employment. Each option has a 10-year term and aligns with Nasdaq Listing Rule 5635(c)(4). Akebia, a biopharmaceutical company focused on improving lives i...
07-02 20:05
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study After Planned Interim Analysis Based On Recommendation From Independent Data Monitoring Committee, Trial Steering Committee
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, are pleased to announce today the decision by US...
06-30 20:09
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Akebia Therapeutics and U.S. Renal Care announced the early termination of the VOICE trial due to significant safety benefits of Vafseo® (vadadustat) in reducing hospitalizations in CKD anemia patients on dialysis. The interim analysis showed non-inferiority and superiority in the primary composite endpoint of mortality and hospitalization, with a win odds ratio of 1.16. Vafseo demonstrated a statistically significant reduction in hospitalization...
06-30 12:00
Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market
While there are already several drugs already approved to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, Shalabh Gupta isn't fazed. As CEO of Unicycive Therapeutics...
06-22 21:56
Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend Expiration Of Composition Of Matter Patent Covering Vafseo
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and it h...
06-10 20:07
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Akebia Therapeutics announced the granting of a new patent for Vafseo (vadadustat), an oral treatment for anemia in chronic kidney disease patients on dialysis. The patent, listed in the Orange Book, extends the composition of matter patent by 5 years, reinforcing Akebia's intellectual property portfolio, which now includes 14 Orange Book-listed patents expiring through 2036. Vafseo, approved in the U.S. in 2025, remains the only oral HIF-PH inhi...
06-10 12:00
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Akebia Therapeutics, a biopharmaceutical company focused on improving the lives of those affected by kidney disease, granted a newly hired employee options to purchase 8,400 shares of its common stock on May 29, 2026. The options were granted as an inducement for the employee to join the company and align with Nasdaq Listing Rule 5635(c)(4). The exercise price is $1.02 per share, equal to the closing price on the grant date. The options vest o...
06-01 20:05
Akebia Therapeutics Earnings Call: Vafseo Drives Transition
Akebia Therapeutics (($AKBA)) has held its Q1 earnings call. Read on for the ma...
05-20 12:48
